Orchestra BioMed Holdings Inc. (OBIO) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for Orchestra BioMed Holdings Inc. (US:OBIO), currently being evaluated. In 2025, Orchestra BioMed Holdings Inc. generated $33.48 Million in revenue and -$49.45 Million in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for Orchestra BioMed Holdings Inc. is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: N/A
- Recent Revenue (2025): $33.48 Million
- Free Cash Flow (2025): -$49.45 Million
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.